Research by DealForma

Decades of context backed by data from the DealForma database

 

Run your analyses better, in less time, with the newest database built for biopharma, medtech, and diagnostics.

Learn MoreSchedule Your Demo

20,378

Licensing Deals

4,034

M&A

5,478

Other Deals

17,730

Funding Rounds

31,012

Company Profiles

26,505

Drug Sales Figures

All of this by stage, disease indication, modality, target

M&A – Biopharma Therapeutics And Platforms – Q1 2023

M&A – Biopharma Therapeutics And Platforms – Q1 2023

Biopharma M&A started to in the first quarter of 2023 after a slow 2022. Major deals included Moderna's acquisition of OriCiro Genomics for $85 million, expanding Moderna's manufacturing capabilities for mRNA vaccines. Pfizer's blockbuster $43 billion acquisition...

Venture & IPO – Medtech

Venture & IPO – Medtech

Venture & IPO - Medtech As the demand for innovative medical technologies continues to grow, many entrepreneurs and investors are exploring ways to finance the development and commercialization of new MedTech products. Two popular options for raising capital in...

M&A – Medtech

M&A – Medtech

M&A – Medtech Medical technology, or MedTech, is a multidisciplinary field that combines technology and medical interventions. It encompasses various technologies, devices, services, products, and solutions that employ medical technology to improve patient care...

R&D Partnerships – Medtech

R&D Partnerships – Medtech

R&D PARTNERSHIPS – MEDTECH As we enter the first quarter of 2023, there is a persistent rise in R&D spending despite the mounting pressure to cut costs, reduce budgets and enhance profit margins. The life sciences sector anticipated an R&D expenditure of...

M&A – Biopharma Therapeutics And Platforms

M&A – Biopharma Therapeutics And Platforms

M&A – Biopharma Therapeutics And Platforms Mergers and Acquisitions are related concepts that refer to consolidating two or more companies into a single entity. In a merger, two or more companies come together to form a new company, while in an acquisition, one...

Biopharma Therapeutics & Platforms Paradigm

Biopharma Therapeutics & Platforms Paradigm

Biopharma Therapeutics & Platforms Paradigm  Biopharmaceutical companies that develop new therapies and health technologies are essential for advancing drug development in its early stages. That's why US biotech firms are highly sought after by private equity...

Biotech and Pharma Deals in 2020

Biotech and Pharma Deals in 2020

Biotech and pharma deals in 2020 soared to an all-time high of 1,154 signed deals with $146.3 billion in total value, defying expectations that the global Covid-19 pandemic would hamper dealmaking. Global healthcare and life sciences R&D partnership activity was...

Biotech and Pharma M&A in 2020

Biotech and Pharma M&A in 2020

Biotech and pharma M&A total deal values slumped in 2020, despite an active year in life sciences dealmaking, with no big standout biopharma deals until late in the second half of the year. It could also be argued that big M&A deals were put on a backburner as...

Life Sciences M&A Tops $240 Billion in 2019

Life Sciences M&A Tops $240 Billion in 2019

This article is a sample from the DealForma Annual Deal Trends Report provided to database subscribers. Data for this analysis was compiled using the DealForma biopharma deals database. We applied initial filters for mergers and acquisitions, therapeutic areas, asset...